Get started

Financials · LFCR

Lifecore Biomedical Inc. (LFCR) financials

For fiscal 2025 (ended May 25, 2025), Lifecore Biomedical Inc. reported $128.87M of revenue and -$38.72M of net income.

Revenue, FY2025
$128.87M
Revenue growth, YoY
+0.5%
Net income, FY2025
-$38.72M
Net margin
-30.0%
Free cash flow, FY2025
-$13.62M
EPS, diluted, FY2025
-$1.27
Cash
$23.04M
Total debt
$160.97M
P/S
1.87
Market cap
$241.5M
Annual revenue$128.87M
FY2016FY2025
Annual net income-$38.72M
FY2016FY2025
Annual free cash flow-$13.62M
FY2016FY2025

LFCR revenue and earnings growth

LFCR revenueQ1 2027$25.32M

Quarter YoY
-18.6%
FY YoY
+0.5%
5Y CAGR
-4.2%
10Y CAGR
-13.3%

LFCR revenue was $25.32M in fiscal Q1 2027 (ended Sep 30, 2026), down 18.6% from a year earlier. For the full fiscal 2025 it was $128.87M, up 0.5% from fiscal 2024. Compound annual growth was -4.2% over 5 years and -13.3% over 10 years. It rose in 5 of the last 10 fiscal years.

LFCR net incomeQ1 2027-$40.08M

LFCR net income was -$40.08M in fiscal Q1 2027 (ended Sep 30, 2026), compared with -$9.99M a year earlier. For the full fiscal 2025 it was -$38.72M, compared with $12.01M in fiscal 2024.

LFCR EPSQ1 2027-$1.08

LFCR diluted EPS was -$1.08 in fiscal Q1 2027 (ended Sep 30, 2026), compared with -$0.29 a year earlier. For the full fiscal 2025 it was -$1.27, compared with $0.33 in fiscal 2024.

LFCR free cash flowQ3 2026$3.58M

LFCR free cash flow was $3.58M in fiscal Q3 2026 (ended Mar 31, 2026), compared with -$4.26M a year earlier. For the full fiscal 2025 it was -$13.62M, compared with -$18.14M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
May 25, 2025
FY2024
May 26, 2024
FY2023
May 28, 2023
FY2022
May 29, 2022
FY2021
May 30, 2021
FY2020
May 31, 2020
FY2019
May 26, 2019
FY2018
May 27, 2018
FY2017
May 28, 2017
FY2016
May 29, 2016
Revenue$128.87M$128.26M$103.27M$111.27M$100.87M$160.07M$557.56M$524.23M$469.78M$476.92M
Cost of revenue$88.57M$86.41M$75.28M$72.20M$61.94M$120.68M$476.56M$445.89M$390.56M$410.14M
Gross profit$40.30M$41.85M$27.98M$39.07M$38.94M$39.39M$81.00M$78.34M$79.21M$66.78M
Research and development$8.26M$8.57M$8.74M$7.84M$6.68M$7.58M$11.47M$12.80M$9.47M$7.23M
Selling, general and admin$44.05M$40.46M$38.97M$34.66M$27.72M$40.67M$62.06M$51.95M$52.49M$46.18M
Operating income-$17.25M-$8.84M-$21.80M-$11.79M-$8.82M-$25.88M$5.47M$13.59M$14.67M-$20.63M
Interest expense--$17.65M$15.55M$8.93M$4.65M---$1.99M
Pre-tax income-$38.67M$9.51M-$63.93M-$20.69M-$29.79M-$30.64M$3.64M$16.40M$14.18M-$19.69M
Income tax$43.0K$183.0K$308.0K-$5.21M-$6.35M-$8.77M$1.52M-$9.36M$4.04M-$7.70M
Net income-$38.72M$12.01M-$99.56M-$116.72M-$32.29M-$38.19M$411.0K$24.83M$10.59M-$11.64M
EPS, basic-$1.27$0.39-$3.32-$3.97-$1.10-$1.31$0.01$0.90$0.39-$0.43
EPS, diluted-$1.27$0.33-$3.32-$3.97-$1.10-$1.31$0.01$0.89$0.38-$0.43
Diluted shares34.8M36.7M30.0M29.5M29.3M29.2M28.6M27.9M27.7M27.0M

Balance sheet

Balance sheet
Line item
FY2025
May 25, 2025
FY2024
May 26, 2024
FY2023
May 28, 2023
FY2022
May 29, 2022
FY2021
May 30, 2021
FY2020
May 31, 2020
FY2019
May 26, 2019
FY2018
May 27, 2018
FY2017
May 28, 2017
FY2016
May 29, 2016
Cash and equivalents$8.27M$8.46M$19.09M$1.64M$1.29M$553.0K$1.47M$3.22M$5.73M$9.97M
Receivables-$31.15M$29.02M$38.31M$31.59M$76.21M$69.56M$53.88M$45.90M$46.41M
Inventory$32.29M$39.98M$40.84M$36.00M$33.93M$66.31M$54.13M$31.82M$23.62M$25.54M
Current assets$85.68M$81.03M$93.88M$116.67M$145.30M$157.11M$133.04M$97.06M$81.28M$86.30M
Goodwill$13.88M$13.88M$13.88M$13.88M$13.88M$33.92M$76.74M$54.51M$54.51M$49.62M
Total assets$239.34M$253.96M$253.54M$274.70M$501.88M$293.50M$519.09M$404.70M$358.61M$342.65M
Current liabilities$30.18M$38.87M$39.29M$176.58M$101.85M$164.39M$137.09M$88.38M$51.45M$56.34M
Short-term debt$3.44M$943.0K$580.0K$98.18M$0$11.55M$9.79M$4.94M$4.94M$7.87M
Long-term debt-$100.82M$84.26M$0$164.90M$101.36M$87.19M$37.36M$42.30M$45.97M
Total debt$130.44M$101.76M$84.84M$98.18M$164.90M$112.92M$96.98M$42.30M$47.24M$53.84M
Total liabilities$191.91M$200.06M$218.46M$186.88M$299.94M$310.27M$248.95M$152.14M$130.46M$130.30M
Shareholders' equity$1.34M$11.31M-$4.23M$87.82M$201.95M$229.84M$270.14M$252.56M$226.61M$210.73M

Cash flow

Cash flow
Line item
FY2025
May 25, 2025
FY2024
May 26, 2024
FY2023
May 28, 2023
FY2022
May 29, 2022
FY2021
May 30, 2021
FY2020
May 31, 2020
FY2019
May 26, 2019
FY2018
May 27, 2018
FY2017
May 28, 2017
FY2016
May 29, 2016
Operating cash flow-$206.0K$257.0K-$17.44M-$22.59M$16.47M-$17.04M$16.02M$19.78M$29.84M$20.76M
Capital expenditures$13.41M$18.39M-$26.23M$19.26M$12.21M$44.73M$33.59M$23.00M$39.70M
Free cash flow-$13.62M-$18.14M--$48.82M-$2.79M-$29.25M-$28.71M-$13.81M$6.83M-$18.93M
Investing cash flow-$6.42M-$18.39M-$4.81M$79.96M-$12.31M-$23.89M-$96.80M-$35.59M-$25.42M-$40.42M
Financing cash flow$6.42M$7.51M$39.70M-$57.02M-$3.42M$40.02M$79.03M$13.29M-$8.80M$15.42M
Stock-based compensation$10.16M$6.20M$3.61M$2.61M$3.36M$2.42M$3.56M$4.40M$3.96M$3.46M
Depreciation and amortization$8.03M$7.95M$13.18M$18.06M$19.87M$18.84M$15.23M$12.41M$10.68M$9.39M

Key ratios

Key ratios
Line item
FY2025
May 25, 2025
FY2024
May 26, 2024
FY2023
May 28, 2023
FY2022
May 29, 2022
FY2021
May 30, 2021
FY2020
May 31, 2020
FY2019
May 26, 2019
FY2018
May 27, 2018
FY2017
May 28, 2017
FY2016
May 29, 2016
Revenue growth, YoY0.5%24.2%-7.2%10.3%-37.0%-71.3%6.4%11.6%-1.5%-11.6%
Net income growth, YoY-------98.3%134.5%--
EPS growth, YoY-------98.9%134.2%--
Gross margin31.3%32.6%27.1%35.1%38.6%24.6%14.5%14.9%16.9%14.0%
Operating margin-13.4%-6.9%-21.1%-10.6%-8.7%-16.2%1.0%2.6%3.1%-4.3%
Net margin-30.0%9.4%-96.4%-104.9%-32.0%-23.9%0.1%4.7%2.3%-2.4%
Free cash flow margin-10.6%-14.1%--43.9%-2.8%-18.3%-5.1%-2.6%1.5%-4.0%
Return on equity-2898.0%106.2%--132.9%-16.0%-16.6%0.2%9.8%4.7%-5.5%
Return on assets-16.2%4.7%-39.3%-42.5%-6.4%-13.0%0.1%6.1%3.0%-3.4%
Current ratio2.842.082.390.661.430.960.971.101.581.53
Debt to equity97.638.99-1.120.820.490.360.170.210.26

Source: XBRL data Lifecore Biomedical Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

LFCR peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
LFCR$128.87M+0.5%-$38.72M-30.0%$241.5M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

LFCR FAQ

9 questions
  • What is LFCR revenue?
    Lifecore Biomedical Inc. (LFCR) reported $128.87M of revenue for fiscal 2025 (ended May 25, 2025). That is up 0.5% from the year before.
  • Is LFCR profitable?
    No. Lifecore Biomedical Inc. reported a net loss of $38.72M for fiscal 2025 (ended May 25, 2025).
  • How much cash and debt does LFCR have?
    Lifecore Biomedical Inc. reported $23.04M in cash and cash equivalents and $160.97M of debt on its most recent balance sheet in SEC filings.
  • How fast is LFCR revenue growing?
    Lifecore Biomedical Inc.'s revenue changed +0.5% in fiscal 2025, to $128.87M. Its compound annual growth rate was -4.2% over 5 years and -13.3% over 10 years.
  • What is LFCR gross margin?
    Lifecore Biomedical Inc.'s gross profit was $40.30M on $128.87M of revenue for fiscal 2025 (ended May 25, 2025), a gross margin of 31.3%.
  • What is LFCR free cash flow?
    Lifecore Biomedical Inc. generated -$13.62M of free cash flow for fiscal 2025 (ended May 25, 2025), which is operating cash flow of -$206.0K less capital expenditures.
  • What is LFCR earnings per share?
    Diluted earnings per share were -$1.27 for fiscal 2025 (ended May 25, 2025), from SEC filings, restated for any stock split those filings show.
  • When did LFCR last report financial results?
    The latest statements here come from Lifecore Biomedical Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this LFCR financial data come from?
    Quantisnow builds these statements from the structured XBRL data Lifecore Biomedical Inc. files with the SEC. It is provided for information only and is not investment advice.